TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26198890

Group type: EXPERIMENTAL
Intervention: Very early mobilisation (n=43) consisting of early and frequent out of bed activities starting within 24 hours of stroke onset for 5 to 30 minutes at least twice a day for seven days
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Very early mobilisation (n=43)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care (n=43)
Number of subjects: 86
Study: 25706622

Group type: EXPERIMENTAL
Intervention: 60 minutes moderate-intensity aerobic and resistance exercise five days/week over 24 weeks (one supervised and four unsupervised sessions)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 45 minutes stretching five days/week over 24 weeks (one supervised and four unsupervised sessions)
Number of subjects: 33
Study: 23602230

Group type: EXPERIMENTAL
Intervention: Micronutrient powder without zinc (group B)
Number of subjects: 2746

Group type: EXPERIMENTAL
Intervention: Micronutrient powder with zinc (group C)
Number of subjects: 2746

Group type: COMPARATOR
Intervention: Non-supplemented control (group A)
Number of subjects: 2746

Group type: EXPERIMENTAL
Intervention: Micronutrient powder groups (B and C)
Number of subjects: 2746
Study: 20800968

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral minimal contact program (MCT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Brochure (bibliotherapy)
Number of subjects: 182
Study: 18757184

Group type: EXPERIMENTAL
Intervention: Capsular polysaccharide-based vaccine (StaphVAX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human immunoglobulin G (IgG) preparation (INH-A21, Veronate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel antigens in pre-clinical trials
Number of subjects: 0
Study: 16024184

Group type: EXPERIMENTAL
Intervention: RODA
Number of subjects: 70

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 70
Study: 15518609

Group type: EXPERIMENTAL
Intervention: Women with CHF
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Men with CHF
Number of subjects: 1591
Study: 10920157

Group type: EXPERIMENTAL
Intervention: Albuterol administered through the spacer device (50 microg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Albuterol administered through the nebulizer (150 microg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Albuterol administered through the spacer device
Number of subjects: 64

Group type: COMPARATOR
Intervention: Albuterol administered through the nebulizer
Number of subjects: 64
Study: 8936492

Group type: EXPERIMENTAL
Intervention: Overnight glucose infusion (5 mg.kg‐1.d‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no glucose infusion)
Number of subjects: 16
Study: 1543310

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine, 2 mg/kg body weight
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 18
Study: 3904464

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multiple injections
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional two-injection treatment
Number of subjects: 45
Study: 3113566

Group type: EXPERIMENTAL
Intervention: Placental grading reported to the clinician responsible for care
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placental grading noted but not reported
Number of subjects: 2000
Study: 31289017

Group type: EXPERIMENTAL
Intervention: Continuous intracoronary adenosine (360 mcg/min)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard intravenous adenosine (140-180 mcg/kg/min)
Number of subjects: 41
Study: 29808819

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (DCB)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Second-generation sirolimus-eluting stent (DES)
Number of subjects: 229
Study: 27692497

Group type: EXPERIMENTAL
Intervention: PHMB-based solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sterile water (Control)
Number of subjects: 40
Study: 25047826

Group type: EXPERIMENTAL
Intervention: Active tDCS with placebo gum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeine gum with sham tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS with placebo gum
Number of subjects: 30
Study: 22385548

Group type: EXPERIMENTAL
Intervention: Nutraceutical drink with red yeast rice (RYR)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nutraceutical drink without red yeast rice (RYR)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 20878941

Group type: EXPERIMENTAL
Intervention: Alcohol-based handrub
Number of subjects: 3317

Group type: COMPARATOR
Intervention: Plain soap and water
Number of subjects: 3317
Study: 19071988

Group type: EXPERIMENTAL
Intervention: Embedding mental action verbs within instructions
Number of subjects: 0
Study: 16189492

Group type: EXPERIMENTAL
Intervention: Toric soft contact lens (TS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspheric soft contact lens (AS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spectacle correction (SC)
Number of subjects: 30
Study: 12776225

Group type: EXPERIMENTAL
Intervention: General movements (GMs) assessment between 3 and 6 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: General movements (GMs) assessment between 9 and 16 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Presence of early asymmetries at both 3-6 and 9-16 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: General movements (GMs) assessment
Number of subjects: 22
Study: 10704160

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nitroglycerin plus Heparin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9346795

Group type: EXPERIMENTAL
Intervention: Piggyback with temporary portocaval shunting
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional liver transplantation with venovenous bypass
Number of subjects: 44
Study: 8263618

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium tocolysis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conservative management with hydration, sedation, and observation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 90
Study: 3518729

Group type: EXPERIMENTAL
Intervention: Treuphadol oblong tablets (500 mg paracetamol)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Treuphadol Plus oblong tablets (500 mg paracetamol, 30 mg codeine phosphate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Treuphadol suppositories (750 mg paracetamol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Commercial tablets (500 mg paracetamol)
Number of subjects: 8
Study: 31103367

Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 32590

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 32590
Study: 30672176

Group type: EXPERIMENTAL
Intervention: Neck-seven-acupoint group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Regular acupuncture group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 90
Study: 26091965

Group type: EXPERIMENTAL
Intervention: DHA-enriched formula (600 mg daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: High oleic acid sunflower seed oil (placebo)
Number of subjects: 138
Study: 25517706

Group type: EXPERIMENTAL
Intervention: Cytisine for 25 days
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Nicotine-replacement therapy for 8 weeks
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Nicotine-replacement therapy
Number of subjects: 1310
Study: 22853325

Group type: EXPERIMENTAL
Intervention: AR + IVR (Assisted Referral + Interactive Voice Recognition follow-up calls)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 900
Study: 20821930

Group type: EXPERIMENTAL
Intervention: iobitridol 350
Number of subjects: 98

Group type: COMPARATOR
Intervention: iopamidol 370
Number of subjects: 98
Study: 17490963

Group type: EXPERIMENTAL
Intervention: Diet containing 550 mg choline x 70 kg(‐1) x d(‐1) for 10 d followed by <50 mg choline x 70 kg(‐1) x d(‐1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Diet containing 550 mg choline x 70 kg(‐1) x d(‐1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Folic acid supplement (400 microg/d)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Incremental amounts of choline added back to the diet
Number of subjects: 57
Study: 16200680

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 100

Group type: COMPARATOR
Intervention: IRM
Number of subjects: 100
Study: 11888044

Group type: EXPERIMENTAL
Intervention: SHARE sex education programme
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intensive teacher training
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Compatibility with existing Personal and Social Education (PSE) provision
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Senior management support
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Competition for curriculum time
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Brevity of lessons
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low priority accorded to PSE by senior management
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Teachers' limited experience and ability in use of role‐play
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nature of the adoption process
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Staff absence and turnover
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Theoretical understanding of the package
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Commitment to the research
Number of subjects: 13
Study: 11079284

Group type: EXPERIMENTAL
Intervention: Sumatriptan tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 0
Study: 8922196

Group type: EXPERIMENTAL
Intervention: Mitomycin C plus vindesine plus etoposide (MEV)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Mitomycin C plus vindesine plus cisplatin (MVP)
Number of subjects: 204
Study: 1305042

Group type: EXPERIMENTAL
Intervention: Ukrain administered intramuscularly (i.m.) or intravenously (i.v.) every one, two or three days in doses of 5 to 50 mg for 7 to 40 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ukrain administered for three years in the dose of 5 to 50 mg/injection in repeated courses
Number of subjects: 19
Study: 4003139

Group type: EXPERIMENTAL
Intervention: Work periods (30, 60, and 120 minutes) during Experiment 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Days with no work periods (control days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work periods of varying lengths (30, 60, and 120 minutes)
Number of subjects: 0
Study: 30872116

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 28759833

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25118333

Group type: EXPERIMENTAL
Intervention: Pet AL (PAL) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reminiscing intervention
Number of subjects: 40
Study: 23764683

Group type: EXPERIMENTAL
Intervention: Famotidine (100 mg twice daily, n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study: 21840734

Group type: EXPERIMENTAL
Intervention: Maximal dose of fluvastatin (80 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Titrated dosing of fluvastatin (starting at 20 mg/day)
Number of subjects: 52
Study: 19640855

Group type: EXPERIMENTAL
Intervention: Health promotion programme consisting of three sessions weekly over 12 weeks (one educational session and two physical activity sessions).
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Health promotion programme
Number of subjects: 921

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 921
Study: 16545704

Group type: EXPERIMENTAL
Intervention: Mandibular widening using distraction osteogenesis
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group with normal occlusion
Number of subjects: 15
Study: 12810336

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulator (VNS) implantation
Number of subjects: 6
Study: 10701034

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with propofol
Number of subjects: 43

Group type: COMPARATOR
Intervention: Anaesthetist-administered midazolam
Number of subjects: 43
Study: 8989196

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (3.0 to 20 micrograms/kg/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 19
Study: 8491010

Group type: EXPERIMENTAL
Intervention: Anterior approach to radiofrequency catheter ablation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Posterior approach to radiofrequency catheter ablation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alternative technique after initial failure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Anterior lesion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Posterior lesion
Number of subjects: 50
Study: 3438646

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29602140

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg
Number of subjects: 1838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1838

Group type: EXPERIMENTAL
Intervention: Simvastatin and Ezetimibe
Number of subjects: 1838
Study: 28606915

Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment
Number of subjects: 2584

Group type: EXPERIMENTAL
Intervention: Baseline plasma FGF21 concentrations
Number of subjects: 2584
Study: 26121303

Group type: EXPERIMENTAL
Intervention: Family Check-Up prevention services
Number of subjects: 79
Study: 23830392

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-treated dental pulp
Number of subjects: 20
Study: 21035866

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser peripheral iridotomy (LPI)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No laser (control)
Number of subjects: 116
Study: 18299307

Group type: EXPERIMENTAL
Intervention: Insulin glargine mixed with rapid-acting insulin analog, administered twice daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) therapy with rapid-acting insulin analog, administered twice daily
Number of subjects: 42
Study: 16781218

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (ASA)
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 14000
Study: 15010555

Group type: EXPERIMENTAL
Intervention: Nevirapine during labour and neonatally
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo arm (control)
Number of subjects: 365
Study: 10730742

Group type: EXPERIMENTAL
Intervention: Video-optical intubation stylet (VOIS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bullard laryngoscope (BL)
Number of subjects: 40
Study: 9413662

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 7978599

Group type: EXPERIMENTAL
Intervention: 2 mg IV naloxone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4 mg IV naloxone
Number of subjects: 14
Study: 2689916

Group type: EXPERIMENTAL
Intervention: Buflomedil chlorhydrate (150 mg intravenous injection in bolus)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4570905

Group type: COMPARATOR
Intervention: Phenoxybenzamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reinforcement
Number of subjects: 10
Study: 30631062

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28457714

Group type: EXPERIMENTAL
Intervention: Educational program aimed at discouraging sugar-sweetened carbonated beverages intake
Number of subjects: 478

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 478
Study: 25219982

Group type: EXPERIMENTAL
Intervention: Retina Implant Alpha IMS
Number of subjects: 9
Study: 23860295

Group type: EXPERIMENTAL
Intervention: Short-acting β2‐agonist (SABA) - 20 µg of inhaled procaterol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22103957

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (MINT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 106
Study: 19398092

Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol and 400 mg progesterone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol and 400 mg progesterone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol and placebo
Number of subjects: 27
Study: 17301636

Group type: EXPERIMENTAL
Intervention: Exercise consultation and exercise information
Number of subjects: 70

Group type: COMPARATOR
Intervention: Exercise information only (Control)
Number of subjects: 70
Study: 15148494

Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Peripheral Blood Progenitor Cells (PBPC)
Number of subjects: 184
Study: 12413372

Group type: EXPERIMENTAL
Intervention: Combination therapy (abciximab and half-dose reteplase)
Number of subjects: 16453

Group type: COMPARATOR
Intervention: Standard dose of reteplase
Number of subjects: 16453

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16453
Study: 9844098

Group type: EXPERIMENTAL
Intervention: Moderate exercise (30-minute sessions of weight-bearing physical education lessons three times weekly for 8 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study: 7536619

Group type: EXPERIMENTAL
Intervention: Gene therapy for cystic fibrosis, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current treatments for cystic fibrosis, details on specific treatments not available
Number of subjects: 0
Study: 1976339

Group type: EXPERIMENTAL
Intervention: xamoterol (200 mg twice a day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 6993253

Group type: EXPERIMENTAL
Intervention: Standard inhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaler with a 32 X 100 mm tube actuated 2 seconds before inhalation
Number of subjects: 0
Study: 29890899

Group type: EXPERIMENTAL
Intervention: 15-minute acute bout of treadmill walking (N=25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 15 minutes of sitting (Control group; N=26)
Number of subjects: 51
Study: 28835058

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg intravenously after general anesthesia induction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine cream with endotracheal tube
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of dexmedetomidine with lidocaine cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (normal saline and liquid paraffin)
Number of subjects: 80
Study: 25936655

Group type: EXPERIMENTAL
Intervention: Computerized interpretation training
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 72

Group type: COMPARATOR
Intervention: Active placebo control
Number of subjects: 72
Study: 23435568

Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 314

Group type: COMPARATOR
Intervention: WGL
Number of subjects: 314
Study: 21425738

Group type: EXPERIMENTAL
Intervention: Exercise with flexible stick training (EF group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tai Chi training (TC group)
Number of subjects: 30
Study: 19246310

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.6‐1.8 mg) plus tropisetron (5 mg/100 ml)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fentanyl (0.8‐1.0 mg) and flurbiprofen axetil (200 mg) plus tropisetron (5 mg/100 ml)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 16551898

Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.1 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (S-group)
Number of subjects: 90
Study: 14631327

Group type: EXPERIMENTAL
Intervention: Insulin plus metformin 1000 mg twice a day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 12
Study: 10847226

Group type: EXPERIMENTAL
Intervention: Progesterone cream 40 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Progesterone cream 20 mg, twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Progesterone cream (both regimens)
Number of subjects: 24
Study: 2065637

Group type: EXPERIMENTAL
Intervention: Zinc supplement (22.5 mg daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 6343572

Group type: EXPERIMENTAL
Intervention: Indomethacin with usual medical therapy
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo with usual medical therapy
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Indomethacin only if usual therapy failed (strategy 2)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Indomethacin with initial medical therapy (strategy 1)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: No indomethacin with surgery as backup (strategy 3)
Number of subjects: 421
Study: 31109481

Group type: EXPERIMENTAL
Intervention: LE BID + qD bromfenac
Number of subjects: 100

Group type: COMPARATOR
Intervention: LE QID + qD bromfenac (control group)
Number of subjects: 100
Study: 29886215

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prosthetic Bypass (BSX)
Number of subjects: 46
Study: 27216875

Group type: EXPERIMENTAL
Intervention: High implementation of STEPs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low implementation of STEPs
Number of subjects: 20
Study: 23048018

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPX)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19